Relmada Therapeutics (RLMD) Enterprise Value (2012 - 2026)
Relmada Therapeutics (RLMD) reported Enterprise Value of -$234.0 million for Q1 2026, down 764.58% year-over-year from $35.2 million in Q1 2025, and down 151.56% on a QoQ basis from -$93.0 million in Q4 2025.
Relmada Therapeutics (RLMD) has 15 years of Enterprise Value data on file, last reported at -$234.0 million in Q1 2026.
- Quarterly Enterprise Value fell 764.58% year-over-year to -$234.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$234.0 million (down 764.58% YoY) and the FY2025 annual result came in at -$93.0 million, down 107.1% from the prior year.
- Enterprise Value retreated to -$234.0 million in Q1 2026 per RLMD's latest filing, from -$93.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$13.9 million in Q3 2025 and bottomed at -$234.0 million in Q1 2026.
- The 5-year median for Enterprise Value is -$96.3 million (2023), against an average of -$109.4 million.
- The widest annual swing landed in 2025, when Enterprise Value soared 74.34%; it then sank 764.58% in 2026.
- Tracing RLMD's Enterprise Value over 5 years: stood at -$148.3 million in 2022, then soared by 35.06% to -$96.3 million in 2023, then surged by 53.38% to -$44.9 million in 2024, then sank by 107.1% to -$93.0 million in 2025, then plunged by 151.56% to -$234.0 million in 2026.
- Per Business Quant, the three latest RLMD Enterprise Value figures stand at -$234.0 million (Q1 2026), -$93.0 million (Q4 2025), and -$13.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | -233.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -233.96 Mn |
| Dec 31, 2025 | -93.01 Mn |
| Sep 30, 2025 | -13.89 Mn |
| Jun 30, 2025 | -20.62 Mn |
| Mar 31, 2025 | -27.06 Mn |
| Dec 31, 2024 | -44.91 Mn |
| Sep 30, 2024 | -54.12 Mn |
| Jun 30, 2024 | -70.44 Mn |
| Mar 31, 2024 | -83.61 Mn |
| Dec 31, 2023 | -96.32 Mn |
| Sep 30, 2023 | -106.27 Mn |
| Jun 30, 2023 | -118.53 Mn |
| Mar 31, 2023 | -132.44 Mn |
| Dec 31, 2022 | -148.32 Mn |
| Sep 30, 2022 | -184.15 Mn |
| Jun 30, 2022 | -211.96 Mn |
| Mar 31, 2022 | -220.65 Mn |
| Dec 31, 2021 | -211.91 Mn |
| Sep 30, 2021 | -88.09 Mn |
| Jun 30, 2021 | -109.07 Mn |
| Mar 31, 2021 | -102.70 Mn |
| Dec 31, 2020 | -117.09 Mn |
| Sep 30, 2020 | -123.14 Mn |
| Jun 30, 2020 | -134.09 Mn |
| Mar 31, 2020 | -114.92 Mn |
| Dec 31, 2019 | -116.44 Mn |
| Sep 30, 2019 | -7.85 Mn |
| Jun 30, 2019 | -9.22 Mn |
| Mar 31, 2019 | -2.05 Mn |
| Dec 31, 2018 | -2.43 Mn |
| Sep 30, 2018 | -887,494.00 |
| Jun 30, 2018 | -2.24 Mn |
| Mar 31, 2018 | -4.26 Mn |
| Dec 31, 2017 | -5.94 Mn |
| Sep 30, 2017 | -4.68 Mn |
| Jun 30, 2017 | -1.71 Mn |
| Mar 31, 2017 | -2.76 Mn |
| Dec 31, 2016 | -4.71 Mn |
| Sep 30, 2016 | -6.22 Mn |
| Jun 30, 2016 | -8.50 Mn |
| Mar 31, 2016 | -11.35 Mn |
| Dec 31, 2015 | -15.13 Mn |
| Sep 30, 2015 | -19.17 Mn |
| Jun 30, 2015 | -22.47 Mn |
| Mar 31, 2015 | -26.96 Mn |
| Dec 31, 2014 | -31.42 Mn |
| Sep 30, 2014 | -27.39 Mn |
| Jun 30, 2014 | -25.56 Mn |
| Mar 31, 2014 | -2.46 Mn |
| Nov 30, 2013 | -6,166.00 |
| Aug 31, 2013 | -15,290.00 |
| Feb 28, 2013 | -7,504.00 |
| Nov 30, 2012 | -10,446.00 |
| Aug 31, 2012 | -8,949.00 |